Article Text
Therapeutics
Randomised controlled trial
Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinux
Statistics from Altmetric.com
Footnotes
-
Competing interests AML has received research funding and consulting honoraria from Roche, Bristol-Myers Squibb and Schering Plough. AK has no disclosures to report.